Key facts
- This page summarizes Tal Zvi Zaks's Form 4 filing for Moderna, Inc. (MRNA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2021, 16:30.
Tal Zvi Zaks - 30 Jun 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- MRNA
- Reported as of
- 30 Jun 2021
- Net transaction value
- -$1,055,350
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2021, 16:30:13 UTC
- Prior SEC filing
- 25 Jun 2021
- Next SEC filing
- 02 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Tal Zvi Zaks filed Form 4 for Moderna, Inc. (MRNA) on 02 Jul 2021.
Change
- Previous filing in this sequence was filed on 25 Jun 2021.
- Current net transaction value: -$1,055,350.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $129,650
- Shares
- +5,000
- Change %
- Price
- $25.93
- Shares after
- 5,000
- Date
- 30 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $1,185,000
- Shares
- -5,000
- Change %
- -100%
- Price
- $237.00
- Shares after
- 0
- Date
- 30 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -4%
- Price
- $0.000000
- Shares after
- 121,120
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $25.93
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.
Footnote F2
25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.